nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—ABL1—esophageal cancer	0.198	0.358	CbGaD
Nilotinib—CA1—esophageal cancer	0.181	0.327	CbGaD
Nilotinib—CA2—esophageal cancer	0.137	0.248	CbGaD
Nilotinib—ABCB1—esophageal cancer	0.0366	0.0662	CbGaD
Nilotinib—ABCG2—Carboplatin—esophageal cancer	0.0209	0.224	CbGbCtD
Nilotinib—ABCG2—Cisplatin—esophageal cancer	0.0179	0.191	CbGbCtD
Nilotinib—CYP2C9—Capecitabine—esophageal cancer	0.0132	0.141	CbGbCtD
Nilotinib—CYP2B6—Cisplatin—esophageal cancer	0.0126	0.135	CbGbCtD
Nilotinib—ABCG2—Methotrexate—esophageal cancer	0.0116	0.124	CbGbCtD
Nilotinib—CYP2C9—Cisplatin—esophageal cancer	0.00665	0.0711	CbGbCtD
Nilotinib—ABCB1—Cisplatin—esophageal cancer	0.00645	0.069	CbGbCtD
Nilotinib—CA3—pericardium—esophageal cancer	0.00463	0.055	CbGeAlD
Nilotinib—ABCB1—Methotrexate—esophageal cancer	0.00419	0.0448	CbGbCtD
Nilotinib—MAPK8—exocrine gland—esophageal cancer	0.00249	0.0296	CbGeAlD
Nilotinib—CA6—exocrine gland—esophageal cancer	0.00179	0.0213	CbGeAlD
Nilotinib—MAPK8—neck—esophageal cancer	0.00159	0.0189	CbGeAlD
Nilotinib—Ponatinib—ABL1—esophageal cancer	0.00132	0.251	CrCbGaD
Nilotinib—CDC42BPB—bronchus—esophageal cancer	0.00118	0.014	CbGeAlD
Nilotinib—CDC42BPB—smooth muscle tissue—esophageal cancer	0.00115	0.0137	CbGeAlD
Nilotinib—Ponatinib—KDR—esophageal cancer	0.00112	0.213	CrCbGaD
Nilotinib—MAPK8—epithelium—esophageal cancer	0.00108	0.0129	CbGeAlD
Nilotinib—MAPK8—bronchus—esophageal cancer	0.00107	0.0127	CbGeAlD
Nilotinib—CDC42BPB—trachea—esophageal cancer	0.00106	0.0126	CbGeAlD
Nilotinib—MAPK8—smooth muscle tissue—esophageal cancer	0.00104	0.0124	CbGeAlD
Nilotinib—KIT—exocrine gland—esophageal cancer	0.00104	0.0124	CbGeAlD
Nilotinib—EPHB2—digestive system—esophageal cancer	0.00103	0.0123	CbGeAlD
Nilotinib—MAPK14—neck—esophageal cancer	0.00101	0.012	CbGeAlD
Nilotinib—MAP4K1—bronchus—esophageal cancer	0.000969	0.0115	CbGeAlD
Nilotinib—TIE1—epithelium—esophageal cancer	0.000939	0.0112	CbGeAlD
Nilotinib—CDC42BPB—digestive system—esophageal cancer	0.000911	0.0108	CbGeAlD
Nilotinib—TIE1—smooth muscle tissue—esophageal cancer	0.000905	0.0108	CbGeAlD
Nilotinib—EPHB3—bronchus—esophageal cancer	0.00088	0.0105	CbGeAlD
Nilotinib—MAPK8—digestive system—esophageal cancer	0.000824	0.0098	CbGeAlD
Nilotinib—Imatinib—ABL1—esophageal cancer	0.000811	0.154	CrCbGaD
Nilotinib—HCK—bronchus—esophageal cancer	0.000808	0.00961	CbGeAlD
Nilotinib—EPHB3—trachea—esophageal cancer	0.00079	0.00939	CbGeAlD
Nilotinib—CDC42BPB—lung—esophageal cancer	0.000761	0.00905	CbGeAlD
Nilotinib—Imatinib—CA1—esophageal cancer	0.000742	0.141	CrCbGaD
Nilotinib—EPHA4—bronchus—esophageal cancer	0.000735	0.00873	CbGeAlD
Nilotinib—HCK—trachea—esophageal cancer	0.000726	0.00863	CbGeAlD
Nilotinib—EPHA3—lung—esophageal cancer	0.000721	0.00858	CbGeAlD
Nilotinib—CA7—trachea—esophageal cancer	0.00071	0.00845	CbGeAlD
Nilotinib—MAPK8—lung—esophageal cancer	0.000688	0.00818	CbGeAlD
Nilotinib—MAPK14—epithelium—esophageal cancer	0.000688	0.00818	CbGeAlD
Nilotinib—EPHB3—digestive system—esophageal cancer	0.00068	0.00808	CbGeAlD
Nilotinib—MAPK14—bronchus—esophageal cancer	0.000677	0.00805	CbGeAlD
Nilotinib—LCK—bronchus—esophageal cancer	0.000675	0.00802	CbGeAlD
Nilotinib—KIT—neck—esophageal cancer	0.000664	0.0079	CbGeAlD
Nilotinib—MAPK14—smooth muscle tissue—esophageal cancer	0.000663	0.00788	CbGeAlD
Nilotinib—EPHA4—trachea—esophageal cancer	0.00066	0.00784	CbGeAlD
Nilotinib—EPHB4—epithelium—esophageal cancer	0.000652	0.00775	CbGeAlD
Nilotinib—PDGFRB—neck—esophageal cancer	0.000649	0.00771	CbGeAlD
Nilotinib—EPHB4—bronchus—esophageal cancer	0.000642	0.00764	CbGeAlD
Nilotinib—EPHA2—epithelium—esophageal cancer	0.00064	0.00761	CbGeAlD
Nilotinib—EPHA2—bronchus—esophageal cancer	0.00063	0.00749	CbGeAlD
Nilotinib—EPHB4—smooth muscle tissue—esophageal cancer	0.000628	0.00747	CbGeAlD
Nilotinib—MAP4K1—lung—esophageal cancer	0.000625	0.00744	CbGeAlD
Nilotinib—HCK—digestive system—esophageal cancer	0.000624	0.00742	CbGeAlD
Nilotinib—TEK—epithelium—esophageal cancer	0.000624	0.00742	CbGeAlD
Nilotinib—CA2—exocrine gland—esophageal cancer	0.000616	0.00732	CbGeAlD
Nilotinib—TEK—bronchus—esophageal cancer	0.000615	0.00731	CbGeAlD
Nilotinib—CA7—digestive system—esophageal cancer	0.000611	0.00727	CbGeAlD
Nilotinib—LCK—trachea—esophageal cancer	0.000606	0.0072	CbGeAlD
Nilotinib—TEK—smooth muscle tissue—esophageal cancer	0.000601	0.00715	CbGeAlD
Nilotinib—TIE1—lung—esophageal cancer	0.000597	0.00709	CbGeAlD
Nilotinib—BLK—lymph node—esophageal cancer	0.000595	0.00708	CbGeAlD
Nilotinib—EPHB6—bronchus—esophageal cancer	0.000587	0.00698	CbGeAlD
Nilotinib—EPHB4—trachea—esophageal cancer	0.000577	0.00686	CbGeAlD
Nilotinib—BRAF—lung—esophageal cancer	0.000572	0.0068	CbGeAlD
Nilotinib—EPHB3—lung—esophageal cancer	0.000567	0.00675	CbGeAlD
Nilotinib—EPHA2—trachea—esophageal cancer	0.000566	0.00673	CbGeAlD
Nilotinib—Imatinib—CA2—esophageal cancer	0.000562	0.107	CrCbGaD
Nilotinib—PDGFRA—smooth muscle tissue—esophageal cancer	0.000545	0.00648	CbGeAlD
Nilotinib—CA9—digestive system—esophageal cancer	0.000537	0.00638	CbGeAlD
Nilotinib—EPHB6—trachea—esophageal cancer	0.000527	0.00627	CbGeAlD
Nilotinib—MAPK11—lymph node—esophageal cancer	0.000525	0.00624	CbGeAlD
Nilotinib—MAPK14—digestive system—esophageal cancer	0.000523	0.00622	CbGeAlD
Nilotinib—HCK—lung—esophageal cancer	0.000522	0.0062	CbGeAlD
Nilotinib—FGR—digestive system—esophageal cancer	0.000521	0.0062	CbGeAlD
Nilotinib—CDC42BPB—lymph node—esophageal cancer	0.00052	0.00619	CbGeAlD
Nilotinib—ABL2—lung—esophageal cancer	0.000518	0.00616	CbGeAlD
Nilotinib—MAP2K5—bronchus—esophageal cancer	0.000502	0.00597	CbGeAlD
Nilotinib—PDGFRA—trachea—esophageal cancer	0.0005	0.00594	CbGeAlD
Nilotinib—EPHB4—digestive system—esophageal cancer	0.000496	0.0059	CbGeAlD
Nilotinib—EPHA3—lymph node—esophageal cancer	0.000493	0.00587	CbGeAlD
Nilotinib—CSF1R—bronchus—esophageal cancer	0.00049	0.00583	CbGeAlD
Nilotinib—EPHA2—digestive system—esophageal cancer	0.000487	0.00579	CbGeAlD
Nilotinib—CSF1R—smooth muscle tissue—esophageal cancer	0.00048	0.0057	CbGeAlD
Nilotinib—CA4—neck—esophageal cancer	0.000475	0.00565	CbGeAlD
Nilotinib—EPHA4—lung—esophageal cancer	0.000474	0.00564	CbGeAlD
Nilotinib—MAPK8—lymph node—esophageal cancer	0.000471	0.0056	CbGeAlD
Nilotinib—CA3—lung—esophageal cancer	0.000468	0.00557	CbGeAlD
Nilotinib—CA12—trachea—esophageal cancer	0.000461	0.00549	CbGeAlD
Nilotinib—KIT—epithelium—esophageal cancer	0.000452	0.00537	CbGeAlD
Nilotinib—MAP2K5—trachea—esophageal cancer	0.000451	0.00536	CbGeAlD
Nilotinib—KIT—bronchus—esophageal cancer	0.000445	0.00529	CbGeAlD
Nilotinib—PDGFRB—epithelium—esophageal cancer	0.000441	0.00525	CbGeAlD
Nilotinib—CSF1R—trachea—esophageal cancer	0.00044	0.00523	CbGeAlD
Nilotinib—MAPK14—lung—esophageal cancer	0.000437	0.0052	CbGeAlD
Nilotinib—KIT—smooth muscle tissue—esophageal cancer	0.000435	0.00518	CbGeAlD
Nilotinib—LCK—lung—esophageal cancer	0.000435	0.00518	CbGeAlD
Nilotinib—FGR—lung—esophageal cancer	0.000435	0.00518	CbGeAlD
Nilotinib—PDGFRB—bronchus—esophageal cancer	0.000435	0.00517	CbGeAlD
Nilotinib—PDGFRA—digestive system—esophageal cancer	0.00043	0.00511	CbGeAlD
Nilotinib—MAP4K1—lymph node—esophageal cancer	0.000428	0.00509	CbGeAlD
Nilotinib—PDGFRB—smooth muscle tissue—esophageal cancer	0.000425	0.00506	CbGeAlD
Nilotinib—EPHB4—lung—esophageal cancer	0.000414	0.00493	CbGeAlD
Nilotinib—UGT1A1—digestive system—esophageal cancer	0.00041	0.00488	CbGeAlD
Nilotinib—TIE1—lymph node—esophageal cancer	0.000408	0.00485	CbGeAlD
Nilotinib—EPHA2—lung—esophageal cancer	0.000406	0.00483	CbGeAlD
Nilotinib—KIT—trachea—esophageal cancer	0.0004	0.00475	CbGeAlD
Nilotinib—CA12—digestive system—esophageal cancer	0.000397	0.00472	CbGeAlD
Nilotinib—TEK—lung—esophageal cancer	0.000396	0.00471	CbGeAlD
Nilotinib—CA2—neck—esophageal cancer	0.000394	0.00468	CbGeAlD
Nilotinib—BRAF—lymph node—esophageal cancer	0.000391	0.00465	CbGeAlD
Nilotinib—PDGFRB—trachea—esophageal cancer	0.00039	0.00464	CbGeAlD
Nilotinib—EPHB3—lymph node—esophageal cancer	0.000388	0.00461	CbGeAlD
Nilotinib—ABL1—bronchus—esophageal cancer	0.000387	0.00461	CbGeAlD
Nilotinib—ABL1—smooth muscle tissue—esophageal cancer	0.000379	0.00451	CbGeAlD
Nilotinib—EPHB6—lung—esophageal cancer	0.000379	0.00451	CbGeAlD
Nilotinib—CSF1R—digestive system—esophageal cancer	0.000379	0.0045	CbGeAlD
Nilotinib—PDGFRA—lung—esophageal cancer	0.000359	0.00427	CbGeAlD
Nilotinib—HCK—lymph node—esophageal cancer	0.000357	0.00424	CbGeAlD
Nilotinib—ABL2—lymph node—esophageal cancer	0.000354	0.00421	CbGeAlD
Nilotinib—ABL1—trachea—esophageal cancer	0.000348	0.00414	CbGeAlD
Nilotinib—KIT—digestive system—esophageal cancer	0.000344	0.00409	CbGeAlD
Nilotinib—PDGFRB—digestive system—esophageal cancer	0.000336	0.00399	CbGeAlD
Nilotinib—CA12—lung—esophageal cancer	0.000332	0.00394	CbGeAlD
Nilotinib—EPHA4—lymph node—esophageal cancer	0.000324	0.00385	CbGeAlD
Nilotinib—MAP2K5—lung—esophageal cancer	0.000324	0.00385	CbGeAlD
Nilotinib—CA3—lymph node—esophageal cancer	0.00032	0.00381	CbGeAlD
Nilotinib—CSF1R—lung—esophageal cancer	0.000316	0.00376	CbGeAlD
Nilotinib—CA1—digestive system—esophageal cancer	0.000314	0.00374	CbGeAlD
Nilotinib—Imatinib—PTGS1—esophageal cancer	0.000309	0.0587	CrCbGaD
Nilotinib—ABL1—digestive system—esophageal cancer	0.000299	0.00356	CbGeAlD
Nilotinib—MAPK14—lymph node—esophageal cancer	0.000299	0.00355	CbGeAlD
Nilotinib—FGR—lymph node—esophageal cancer	0.000298	0.00354	CbGeAlD
Nilotinib—LCK—lymph node—esophageal cancer	0.000298	0.00354	CbGeAlD
Nilotinib—KIT—lung—esophageal cancer	0.000287	0.00341	CbGeAlD
Nilotinib—CA4—trachea—esophageal cancer	0.000286	0.0034	CbGeAlD
Nilotinib—EPHB4—lymph node—esophageal cancer	0.000283	0.00337	CbGeAlD
Nilotinib—PDGFRB—lung—esophageal cancer	0.00028	0.00333	CbGeAlD
Nilotinib—EPHA2—lymph node—esophageal cancer	0.000278	0.00331	CbGeAlD
Nilotinib—TEK—lymph node—esophageal cancer	0.000271	0.00322	CbGeAlD
Nilotinib—CA2—epithelium—esophageal cancer	0.000268	0.00319	CbGeAlD
Nilotinib—CA2—bronchus—esophageal cancer	0.000264	0.00314	CbGeAlD
Nilotinib—CA1—lung—esophageal cancer	0.000263	0.00312	CbGeAlD
Nilotinib—EPHB6—lymph node—esophageal cancer	0.000259	0.00308	CbGeAlD
Nilotinib—CA2—smooth muscle tissue—esophageal cancer	0.000258	0.00307	CbGeAlD
Nilotinib—ABL1—lung—esophageal cancer	0.00025	0.00297	CbGeAlD
Nilotinib—CA4—digestive system—esophageal cancer	0.000246	0.00292	CbGeAlD
Nilotinib—PDGFRA—lymph node—esophageal cancer	0.000246	0.00292	CbGeAlD
Nilotinib—Ponatinib—ABCB1—esophageal cancer	0.000244	0.0464	CrCbGaD
Nilotinib—CA2—trachea—esophageal cancer	0.000237	0.00282	CbGeAlD
Nilotinib—CYP2B6—bronchus—esophageal cancer	0.000225	0.00268	CbGeAlD
Nilotinib—MAP2K5—lymph node—esophageal cancer	0.000222	0.00264	CbGeAlD
Nilotinib—CSF1R—lymph node—esophageal cancer	0.000216	0.00257	CbGeAlD
Nilotinib—CA4—lung—esophageal cancer	0.000205	0.00244	CbGeAlD
Nilotinib—CA2—digestive system—esophageal cancer	0.000204	0.00242	CbGeAlD
Nilotinib—KIT—lymph node—esophageal cancer	0.000196	0.00234	CbGeAlD
Nilotinib—PDGFRB—lymph node—esophageal cancer	0.000192	0.00228	CbGeAlD
Nilotinib—Nasopharyngitis—Capecitabine—esophageal cancer	0.00018	0.00192	CcSEcCtD
Nilotinib—CA1—lymph node—esophageal cancer	0.00018	0.00214	CbGeAlD
Nilotinib—Sepsis—Methotrexate—esophageal cancer	0.000179	0.00192	CcSEcCtD
Nilotinib—Gastritis—Capecitabine—esophageal cancer	0.000178	0.00191	CcSEcCtD
Nilotinib—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000177	0.0019	CcSEcCtD
Nilotinib—Muscular weakness—Capecitabine—esophageal cancer	0.000177	0.0019	CcSEcCtD
Nilotinib—Eye disorder—Cisplatin—esophageal cancer	0.000176	0.00189	CcSEcCtD
Nilotinib—Tinnitus—Cisplatin—esophageal cancer	0.000176	0.00188	CcSEcCtD
Nilotinib—Cardiac disorder—Cisplatin—esophageal cancer	0.000175	0.00187	CcSEcCtD
Nilotinib—Flushing—Cisplatin—esophageal cancer	0.000175	0.00187	CcSEcCtD
Nilotinib—Abdominal distension—Capecitabine—esophageal cancer	0.000175	0.00187	CcSEcCtD
Nilotinib—CYP2B6—digestive system—esophageal cancer	0.000174	0.00207	CbGeAlD
Nilotinib—Influenza—Capecitabine—esophageal cancer	0.000174	0.00186	CcSEcCtD
Nilotinib—CYP2C9—digestive system—esophageal cancer	0.000172	0.00205	CbGeAlD
Nilotinib—Diabetes mellitus—Methotrexate—esophageal cancer	0.000172	0.00184	CcSEcCtD
Nilotinib—ABL1—lymph node—esophageal cancer	0.000171	0.00203	CbGeAlD
Nilotinib—Photosensitivity—Methotrexate—esophageal cancer	0.00017	0.00182	CcSEcCtD
Nilotinib—Immune system disorder—Cisplatin—esophageal cancer	0.00017	0.00182	CcSEcCtD
Nilotinib—CA2—lung—esophageal cancer	0.00017	0.00202	CbGeAlD
Nilotinib—Mediastinal disorder—Cisplatin—esophageal cancer	0.00017	0.00182	CcSEcCtD
Nilotinib—Angina pectoris—Capecitabine—esophageal cancer	0.000169	0.00181	CcSEcCtD
Nilotinib—Arrhythmia—Cisplatin—esophageal cancer	0.000168	0.0018	CcSEcCtD
Nilotinib—Bronchitis—Capecitabine—esophageal cancer	0.000167	0.00179	CcSEcCtD
Nilotinib—Alopecia—Cisplatin—esophageal cancer	0.000167	0.00179	CcSEcCtD
Nilotinib—Abdominal discomfort—Capecitabine—esophageal cancer	0.000166	0.00178	CcSEcCtD
Nilotinib—Pancytopenia—Capecitabine—esophageal cancer	0.000165	0.00177	CcSEcCtD
Nilotinib—Malnutrition—Cisplatin—esophageal cancer	0.000164	0.00176	CcSEcCtD
Nilotinib—Erythema—Cisplatin—esophageal cancer	0.000164	0.00176	CcSEcCtD
Nilotinib—Dysuria—Capecitabine—esophageal cancer	0.000162	0.00174	CcSEcCtD
Nilotinib—Neutropenia—Capecitabine—esophageal cancer	0.000162	0.00174	CcSEcCtD
Nilotinib—Flatulence—Cisplatin—esophageal cancer	0.000162	0.00173	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000161	0.00173	CcSEcCtD
Nilotinib—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000159	0.0017	CcSEcCtD
Nilotinib—Weight increased—Capecitabine—esophageal cancer	0.000158	0.00169	CcSEcCtD
Nilotinib—Muscle spasms—Cisplatin—esophageal cancer	0.000158	0.00169	CcSEcCtD
Nilotinib—ABCG2—lung—esophageal cancer	0.000158	0.00187	CbGeAlD
Nilotinib—Weight decreased—Capecitabine—esophageal cancer	0.000157	0.00168	CcSEcCtD
Nilotinib—Hyperglycaemia—Capecitabine—esophageal cancer	0.000157	0.00168	CcSEcCtD
Nilotinib—Pneumonia—Capecitabine—esophageal cancer	0.000156	0.00167	CcSEcCtD
Nilotinib—Infestation NOS—Capecitabine—esophageal cancer	0.000155	0.00166	CcSEcCtD
Nilotinib—Infestation—Capecitabine—esophageal cancer	0.000155	0.00166	CcSEcCtD
Nilotinib—Vision blurred—Cisplatin—esophageal cancer	0.000155	0.00166	CcSEcCtD
Nilotinib—Tremor—Cisplatin—esophageal cancer	0.000154	0.00165	CcSEcCtD
Nilotinib—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000153	0.00164	CcSEcCtD
Nilotinib—Lethargy—Methotrexate—esophageal cancer	0.000153	0.00164	CcSEcCtD
Nilotinib—Ill-defined disorder—Cisplatin—esophageal cancer	0.000152	0.00163	CcSEcCtD
Nilotinib—Renal failure—Capecitabine—esophageal cancer	0.000152	0.00163	CcSEcCtD
Nilotinib—Myocardial infarction—Capecitabine—esophageal cancer	0.000152	0.00163	CcSEcCtD
Nilotinib—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000152	0.00163	CcSEcCtD
Nilotinib—Anaemia—Cisplatin—esophageal cancer	0.000152	0.00163	CcSEcCtD
Nilotinib—Jaundice—Capecitabine—esophageal cancer	0.000151	0.00162	CcSEcCtD
Nilotinib—Stomatitis—Capecitabine—esophageal cancer	0.000151	0.00162	CcSEcCtD
Nilotinib—Urinary tract infection—Capecitabine—esophageal cancer	0.00015	0.00161	CcSEcCtD
Nilotinib—Conjunctivitis—Capecitabine—esophageal cancer	0.00015	0.00161	CcSEcCtD
Nilotinib—Imatinib—ABCB1—esophageal cancer	0.00015	0.0285	CrCbGaD
Nilotinib—Malaise—Cisplatin—esophageal cancer	0.000148	0.00159	CcSEcCtD
Nilotinib—Haematuria—Capecitabine—esophageal cancer	0.000148	0.00158	CcSEcCtD
Nilotinib—Leukopenia—Cisplatin—esophageal cancer	0.000147	0.00157	CcSEcCtD
Nilotinib—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000146	0.00157	CcSEcCtD
Nilotinib—Epistaxis—Capecitabine—esophageal cancer	0.000146	0.00156	CcSEcCtD
Nilotinib—CYP2B6—lung—esophageal cancer	0.000145	0.00173	CbGeAlD
Nilotinib—Bradycardia—Capecitabine—esophageal cancer	0.000141	0.00152	CcSEcCtD
Nilotinib—CA4—lymph node—esophageal cancer	0.00014	0.00167	CbGeAlD
Nilotinib—Myalgia—Cisplatin—esophageal cancer	0.00014	0.0015	CcSEcCtD
Nilotinib—Haemoglobin—Capecitabine—esophageal cancer	0.00014	0.0015	CcSEcCtD
Nilotinib—Rhinitis—Capecitabine—esophageal cancer	0.000139	0.00149	CcSEcCtD
Nilotinib—Anxiety—Cisplatin—esophageal cancer	0.000139	0.00149	CcSEcCtD
Nilotinib—Haemorrhage—Capecitabine—esophageal cancer	0.000139	0.00149	CcSEcCtD
Nilotinib—Hepatitis—Capecitabine—esophageal cancer	0.000139	0.00149	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000139	0.00149	CcSEcCtD
Nilotinib—Hypoaesthesia—Capecitabine—esophageal cancer	0.000138	0.00148	CcSEcCtD
Nilotinib—Discomfort—Cisplatin—esophageal cancer	0.000138	0.00148	CcSEcCtD
Nilotinib—Pharyngitis—Capecitabine—esophageal cancer	0.000138	0.00148	CcSEcCtD
Nilotinib—Urinary tract disorder—Capecitabine—esophageal cancer	0.000137	0.00147	CcSEcCtD
Nilotinib—Oedema peripheral—Capecitabine—esophageal cancer	0.000137	0.00147	CcSEcCtD
Nilotinib—Connective tissue disorder—Capecitabine—esophageal cancer	0.000137	0.00146	CcSEcCtD
Nilotinib—Urethral disorder—Capecitabine—esophageal cancer	0.000136	0.00146	CcSEcCtD
Nilotinib—Breast disorder—Methotrexate—esophageal cancer	0.000135	0.00145	CcSEcCtD
Nilotinib—Oedema—Cisplatin—esophageal cancer	0.000134	0.00144	CcSEcCtD
Nilotinib—Visual impairment—Capecitabine—esophageal cancer	0.000134	0.00144	CcSEcCtD
Nilotinib—Infection—Cisplatin—esophageal cancer	0.000133	0.00143	CcSEcCtD
Nilotinib—CYP3A4—digestive system—esophageal cancer	0.000131	0.00156	CbGeAlD
Nilotinib—Erythema multiforme—Capecitabine—esophageal cancer	0.000131	0.00141	CcSEcCtD
Nilotinib—Nervous system disorder—Cisplatin—esophageal cancer	0.000131	0.00141	CcSEcCtD
Nilotinib—Thrombocytopenia—Cisplatin—esophageal cancer	0.000131	0.00141	CcSEcCtD
Nilotinib—Tachycardia—Cisplatin—esophageal cancer	0.000131	0.0014	CcSEcCtD
Nilotinib—Skin disorder—Cisplatin—esophageal cancer	0.00013	0.00139	CcSEcCtD
Nilotinib—Eye disorder—Capecitabine—esophageal cancer	0.00013	0.00139	CcSEcCtD
Nilotinib—Tinnitus—Capecitabine—esophageal cancer	0.00013	0.00139	CcSEcCtD
Nilotinib—Hyperhidrosis—Cisplatin—esophageal cancer	0.00013	0.00139	CcSEcCtD
Nilotinib—CYP2D6—digestive system—esophageal cancer	0.000129	0.00154	CbGeAlD
Nilotinib—Cardiac disorder—Capecitabine—esophageal cancer	0.000129	0.00138	CcSEcCtD
Nilotinib—Flushing—Capecitabine—esophageal cancer	0.000129	0.00138	CcSEcCtD
Nilotinib—Eosinophilia—Methotrexate—esophageal cancer	0.000128	0.00137	CcSEcCtD
Nilotinib—Anorexia—Cisplatin—esophageal cancer	0.000128	0.00137	CcSEcCtD
Nilotinib—Pancreatitis—Methotrexate—esophageal cancer	0.000127	0.00136	CcSEcCtD
Nilotinib—Angiopathy—Capecitabine—esophageal cancer	0.000126	0.00135	CcSEcCtD
Nilotinib—Immune system disorder—Capecitabine—esophageal cancer	0.000126	0.00135	CcSEcCtD
Nilotinib—Mediastinal disorder—Capecitabine—esophageal cancer	0.000125	0.00134	CcSEcCtD
Nilotinib—Hypotension—Cisplatin—esophageal cancer	0.000125	0.00134	CcSEcCtD
Nilotinib—Chills—Capecitabine—esophageal cancer	0.000125	0.00134	CcSEcCtD
Nilotinib—Arrhythmia—Capecitabine—esophageal cancer	0.000124	0.00133	CcSEcCtD
Nilotinib—Abdominal discomfort—Methotrexate—esophageal cancer	0.000124	0.00133	CcSEcCtD
Nilotinib—Alopecia—Capecitabine—esophageal cancer	0.000123	0.00132	CcSEcCtD
Nilotinib—Pancytopenia—Methotrexate—esophageal cancer	0.000123	0.00132	CcSEcCtD
Nilotinib—ABCB1—epithelium—esophageal cancer	0.000122	0.00145	CbGeAlD
Nilotinib—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000122	0.00131	CcSEcCtD
Nilotinib—Mental disorder—Capecitabine—esophageal cancer	0.000122	0.0013	CcSEcCtD
Nilotinib—Malnutrition—Capecitabine—esophageal cancer	0.000121	0.0013	CcSEcCtD
Nilotinib—Erythema—Capecitabine—esophageal cancer	0.000121	0.0013	CcSEcCtD
Nilotinib—Neutropenia—Methotrexate—esophageal cancer	0.000121	0.0013	CcSEcCtD
Nilotinib—Dysuria—Methotrexate—esophageal cancer	0.000121	0.0013	CcSEcCtD
Nilotinib—Paraesthesia—Cisplatin—esophageal cancer	0.00012	0.00129	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00012	0.00129	CcSEcCtD
Nilotinib—Dyspnoea—Cisplatin—esophageal cancer	0.000119	0.00128	CcSEcCtD
Nilotinib—Flatulence—Capecitabine—esophageal cancer	0.000119	0.00128	CcSEcCtD
Nilotinib—Erectile dysfunction—Methotrexate—esophageal cancer	0.000119	0.00128	CcSEcCtD
Nilotinib—Dysgeusia—Capecitabine—esophageal cancer	0.000118	0.00127	CcSEcCtD
Nilotinib—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000118	0.00126	CcSEcCtD
Nilotinib—Back pain—Capecitabine—esophageal cancer	0.000117	0.00125	CcSEcCtD
Nilotinib—Decreased appetite—Cisplatin—esophageal cancer	0.000116	0.00125	CcSEcCtD
Nilotinib—CA2—lymph node—esophageal cancer	0.000116	0.00138	CbGeAlD
Nilotinib—Muscle spasms—Capecitabine—esophageal cancer	0.000116	0.00125	CcSEcCtD
Nilotinib—Pneumonia—Methotrexate—esophageal cancer	0.000116	0.00124	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000116	0.00124	CcSEcCtD
Nilotinib—Infestation NOS—Methotrexate—esophageal cancer	0.000115	0.00123	CcSEcCtD
Nilotinib—Infestation—Methotrexate—esophageal cancer	0.000115	0.00123	CcSEcCtD
Nilotinib—Pain—Cisplatin—esophageal cancer	0.000115	0.00123	CcSEcCtD
Nilotinib—Vision blurred—Capecitabine—esophageal cancer	0.000114	0.00122	CcSEcCtD
Nilotinib—Tremor—Capecitabine—esophageal cancer	0.000113	0.00121	CcSEcCtD
Nilotinib—Renal failure—Methotrexate—esophageal cancer	0.000113	0.00121	CcSEcCtD
Nilotinib—Stomatitis—Methotrexate—esophageal cancer	0.000112	0.0012	CcSEcCtD
Nilotinib—Ill-defined disorder—Capecitabine—esophageal cancer	0.000112	0.0012	CcSEcCtD
Nilotinib—Conjunctivitis—Methotrexate—esophageal cancer	0.000112	0.0012	CcSEcCtD
Nilotinib—Anaemia—Capecitabine—esophageal cancer	0.000112	0.0012	CcSEcCtD
Nilotinib—Feeling abnormal—Cisplatin—esophageal cancer	0.00011	0.00118	CcSEcCtD
Nilotinib—Haematuria—Methotrexate—esophageal cancer	0.00011	0.00118	CcSEcCtD
Nilotinib—Malaise—Capecitabine—esophageal cancer	0.000109	0.00117	CcSEcCtD
Nilotinib—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000109	0.00117	CcSEcCtD
Nilotinib—Epistaxis—Methotrexate—esophageal cancer	0.000109	0.00116	CcSEcCtD
Nilotinib—Vertigo—Capecitabine—esophageal cancer	0.000109	0.00116	CcSEcCtD
Nilotinib—Syncope—Capecitabine—esophageal cancer	0.000109	0.00116	CcSEcCtD
Nilotinib—Leukopenia—Capecitabine—esophageal cancer	0.000108	0.00116	CcSEcCtD
Nilotinib—ABCB1—trachea—esophageal cancer	0.000108	0.00129	CbGeAlD
Nilotinib—ABCG2—lymph node—esophageal cancer	0.000108	0.00128	CbGeAlD
Nilotinib—Palpitations—Capecitabine—esophageal cancer	0.000107	0.00115	CcSEcCtD
Nilotinib—Loss of consciousness—Capecitabine—esophageal cancer	0.000106	0.00114	CcSEcCtD
Nilotinib—Body temperature increased—Cisplatin—esophageal cancer	0.000106	0.00113	CcSEcCtD
Nilotinib—Cough—Capecitabine—esophageal cancer	0.000106	0.00113	CcSEcCtD
Nilotinib—Hypertension—Capecitabine—esophageal cancer	0.000104	0.00112	CcSEcCtD
Nilotinib—Haemoglobin—Methotrexate—esophageal cancer	0.000104	0.00111	CcSEcCtD
Nilotinib—Haemorrhage—Methotrexate—esophageal cancer	0.000103	0.00111	CcSEcCtD
Nilotinib—Hepatitis—Methotrexate—esophageal cancer	0.000103	0.00111	CcSEcCtD
Nilotinib—Arthralgia—Capecitabine—esophageal cancer	0.000103	0.0011	CcSEcCtD
Nilotinib—Chest pain—Capecitabine—esophageal cancer	0.000103	0.0011	CcSEcCtD
Nilotinib—Myalgia—Capecitabine—esophageal cancer	0.000103	0.0011	CcSEcCtD
Nilotinib—Pharyngitis—Methotrexate—esophageal cancer	0.000103	0.0011	CcSEcCtD
Nilotinib—Anxiety—Capecitabine—esophageal cancer	0.000103	0.0011	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000102	0.0011	CcSEcCtD
Nilotinib—Urinary tract disorder—Methotrexate—esophageal cancer	0.000102	0.00109	CcSEcCtD
Nilotinib—Discomfort—Capecitabine—esophageal cancer	0.000102	0.00109	CcSEcCtD
Nilotinib—Urethral disorder—Methotrexate—esophageal cancer	0.000101	0.00109	CcSEcCtD
Nilotinib—Dry mouth—Capecitabine—esophageal cancer	0.000101	0.00108	CcSEcCtD
Nilotinib—Visual impairment—Methotrexate—esophageal cancer	9.97e-05	0.00107	CcSEcCtD
Nilotinib—Confusional state—Capecitabine—esophageal cancer	9.96e-05	0.00107	CcSEcCtD
Nilotinib—Oedema—Capecitabine—esophageal cancer	9.87e-05	0.00106	CcSEcCtD
Nilotinib—Hypersensitivity—Cisplatin—esophageal cancer	9.87e-05	0.00106	CcSEcCtD
Nilotinib—Infection—Capecitabine—esophageal cancer	9.81e-05	0.00105	CcSEcCtD
Nilotinib—Erythema multiforme—Methotrexate—esophageal cancer	9.78e-05	0.00105	CcSEcCtD
Nilotinib—Shock—Capecitabine—esophageal cancer	9.72e-05	0.00104	CcSEcCtD
Nilotinib—Nervous system disorder—Capecitabine—esophageal cancer	9.68e-05	0.00104	CcSEcCtD
Nilotinib—Eye disorder—Methotrexate—esophageal cancer	9.67e-05	0.00104	CcSEcCtD
Nilotinib—Thrombocytopenia—Capecitabine—esophageal cancer	9.67e-05	0.00104	CcSEcCtD
Nilotinib—Tinnitus—Methotrexate—esophageal cancer	9.65e-05	0.00103	CcSEcCtD
Nilotinib—Tachycardia—Capecitabine—esophageal cancer	9.64e-05	0.00103	CcSEcCtD
Nilotinib—Asthenia—Cisplatin—esophageal cancer	9.61e-05	0.00103	CcSEcCtD
Nilotinib—Cardiac disorder—Methotrexate—esophageal cancer	9.6e-05	0.00103	CcSEcCtD
Nilotinib—Skin disorder—Capecitabine—esophageal cancer	9.59e-05	0.00103	CcSEcCtD
Nilotinib—Hyperhidrosis—Capecitabine—esophageal cancer	9.55e-05	0.00102	CcSEcCtD
Nilotinib—Anorexia—Capecitabine—esophageal cancer	9.41e-05	0.00101	CcSEcCtD
Nilotinib—Angiopathy—Methotrexate—esophageal cancer	9.39e-05	0.00101	CcSEcCtD
Nilotinib—Immune system disorder—Methotrexate—esophageal cancer	9.35e-05	0.001	CcSEcCtD
Nilotinib—Mediastinal disorder—Methotrexate—esophageal cancer	9.33e-05	0.000999	CcSEcCtD
Nilotinib—ABCB1—digestive system—esophageal cancer	9.31e-05	0.00111	CbGeAlD
Nilotinib—Chills—Methotrexate—esophageal cancer	9.28e-05	0.000995	CcSEcCtD
Nilotinib—Hypotension—Capecitabine—esophageal cancer	9.23e-05	0.000989	CcSEcCtD
Nilotinib—Diarrhoea—Cisplatin—esophageal cancer	9.17e-05	0.000982	CcSEcCtD
Nilotinib—Alopecia—Methotrexate—esophageal cancer	9.14e-05	0.00098	CcSEcCtD
Nilotinib—Mental disorder—Methotrexate—esophageal cancer	9.06e-05	0.000971	CcSEcCtD
Nilotinib—Erythema—Methotrexate—esophageal cancer	9.01e-05	0.000965	CcSEcCtD
Nilotinib—Malnutrition—Methotrexate—esophageal cancer	9.01e-05	0.000965	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Capecitabine—esophageal cancer	9e-05	0.000964	CcSEcCtD
Nilotinib—Insomnia—Capecitabine—esophageal cancer	8.93e-05	0.000957	CcSEcCtD
Nilotinib—Paraesthesia—Capecitabine—esophageal cancer	8.87e-05	0.00095	CcSEcCtD
Nilotinib—Dysgeusia—Methotrexate—esophageal cancer	8.82e-05	0.000945	CcSEcCtD
Nilotinib—Dyspnoea—Capecitabine—esophageal cancer	8.8e-05	0.000943	CcSEcCtD
Nilotinib—Back pain—Methotrexate—esophageal cancer	8.71e-05	0.000933	CcSEcCtD
Nilotinib—Dyspepsia—Capecitabine—esophageal cancer	8.69e-05	0.000931	CcSEcCtD
Nilotinib—Decreased appetite—Capecitabine—esophageal cancer	8.58e-05	0.00092	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Capecitabine—esophageal cancer	8.53e-05	0.000913	CcSEcCtD
Nilotinib—Vomiting—Cisplatin—esophageal cancer	8.52e-05	0.000913	CcSEcCtD
Nilotinib—Fatigue—Capecitabine—esophageal cancer	8.51e-05	0.000912	CcSEcCtD
Nilotinib—Vision blurred—Methotrexate—esophageal cancer	8.49e-05	0.000909	CcSEcCtD
Nilotinib—Rash—Cisplatin—esophageal cancer	8.45e-05	0.000905	CcSEcCtD
Nilotinib—Pain—Capecitabine—esophageal cancer	8.44e-05	0.000905	CcSEcCtD
Nilotinib—Constipation—Capecitabine—esophageal cancer	8.44e-05	0.000905	CcSEcCtD
Nilotinib—Dermatitis—Cisplatin—esophageal cancer	8.44e-05	0.000904	CcSEcCtD
Nilotinib—Ill-defined disorder—Methotrexate—esophageal cancer	8.36e-05	0.000895	CcSEcCtD
Nilotinib—Anaemia—Methotrexate—esophageal cancer	8.33e-05	0.000892	CcSEcCtD
Nilotinib—Feeling abnormal—Capecitabine—esophageal cancer	8.14e-05	0.000872	CcSEcCtD
Nilotinib—Malaise—Methotrexate—esophageal cancer	8.12e-05	0.00087	CcSEcCtD
Nilotinib—Vertigo—Methotrexate—esophageal cancer	8.09e-05	0.000867	CcSEcCtD
Nilotinib—Gastrointestinal pain—Capecitabine—esophageal cancer	8.07e-05	0.000865	CcSEcCtD
Nilotinib—Leukopenia—Methotrexate—esophageal cancer	8.06e-05	0.000864	CcSEcCtD
Nilotinib—Nausea—Cisplatin—esophageal cancer	7.96e-05	0.000853	CcSEcCtD
Nilotinib—Cough—Methotrexate—esophageal cancer	7.86e-05	0.000842	CcSEcCtD
Nilotinib—Urticaria—Capecitabine—esophageal cancer	7.84e-05	0.000841	CcSEcCtD
Nilotinib—Abdominal pain—Capecitabine—esophageal cancer	7.81e-05	0.000836	CcSEcCtD
Nilotinib—Body temperature increased—Capecitabine—esophageal cancer	7.81e-05	0.000836	CcSEcCtD
Nilotinib—ABCB1—lung—esophageal cancer	7.77e-05	0.000924	CbGeAlD
Nilotinib—Arthralgia—Methotrexate—esophageal cancer	7.67e-05	0.000822	CcSEcCtD
Nilotinib—Myalgia—Methotrexate—esophageal cancer	7.67e-05	0.000822	CcSEcCtD
Nilotinib—Chest pain—Methotrexate—esophageal cancer	7.67e-05	0.000822	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	7.62e-05	0.000816	CcSEcCtD
Nilotinib—Discomfort—Methotrexate—esophageal cancer	7.58e-05	0.000812	CcSEcCtD
Nilotinib—Confusional state—Methotrexate—esophageal cancer	7.41e-05	0.000794	CcSEcCtD
Nilotinib—Infection—Methotrexate—esophageal cancer	7.3e-05	0.000782	CcSEcCtD
Nilotinib—Hypersensitivity—Capecitabine—esophageal cancer	7.28e-05	0.000779	CcSEcCtD
Nilotinib—Nervous system disorder—Methotrexate—esophageal cancer	7.21e-05	0.000772	CcSEcCtD
Nilotinib—Thrombocytopenia—Methotrexate—esophageal cancer	7.2e-05	0.000771	CcSEcCtD
Nilotinib—Skin disorder—Methotrexate—esophageal cancer	7.14e-05	0.000765	CcSEcCtD
Nilotinib—Hyperhidrosis—Methotrexate—esophageal cancer	7.11e-05	0.000761	CcSEcCtD
Nilotinib—Asthenia—Capecitabine—esophageal cancer	7.08e-05	0.000759	CcSEcCtD
Nilotinib—Anorexia—Methotrexate—esophageal cancer	7.01e-05	0.000751	CcSEcCtD
Nilotinib—Pruritus—Capecitabine—esophageal cancer	6.99e-05	0.000749	CcSEcCtD
Nilotinib—Hypotension—Methotrexate—esophageal cancer	6.87e-05	0.000736	CcSEcCtD
Nilotinib—Diarrhoea—Capecitabine—esophageal cancer	6.76e-05	0.000724	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Methotrexate—esophageal cancer	6.7e-05	0.000718	CcSEcCtD
Nilotinib—Insomnia—Methotrexate—esophageal cancer	6.65e-05	0.000712	CcSEcCtD
Nilotinib—Paraesthesia—Methotrexate—esophageal cancer	6.6e-05	0.000707	CcSEcCtD
Nilotinib—Dyspnoea—Methotrexate—esophageal cancer	6.55e-05	0.000702	CcSEcCtD
Nilotinib—Dizziness—Capecitabine—esophageal cancer	6.53e-05	0.0007	CcSEcCtD
Nilotinib—Dyspepsia—Methotrexate—esophageal cancer	6.47e-05	0.000693	CcSEcCtD
Nilotinib—Decreased appetite—Methotrexate—esophageal cancer	6.39e-05	0.000685	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Methotrexate—esophageal cancer	6.35e-05	0.00068	CcSEcCtD
Nilotinib—Fatigue—Methotrexate—esophageal cancer	6.34e-05	0.000679	CcSEcCtD
Nilotinib—Pain—Methotrexate—esophageal cancer	6.29e-05	0.000674	CcSEcCtD
Nilotinib—Vomiting—Capecitabine—esophageal cancer	6.28e-05	0.000673	CcSEcCtD
Nilotinib—Rash—Capecitabine—esophageal cancer	6.23e-05	0.000667	CcSEcCtD
Nilotinib—Dermatitis—Capecitabine—esophageal cancer	6.22e-05	0.000666	CcSEcCtD
Nilotinib—Headache—Capecitabine—esophageal cancer	6.19e-05	0.000663	CcSEcCtD
Nilotinib—Feeling abnormal—Methotrexate—esophageal cancer	6.06e-05	0.000649	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methotrexate—esophageal cancer	6.01e-05	0.000644	CcSEcCtD
Nilotinib—Nausea—Capecitabine—esophageal cancer	5.87e-05	0.000628	CcSEcCtD
Nilotinib—Urticaria—Methotrexate—esophageal cancer	5.84e-05	0.000626	CcSEcCtD
Nilotinib—Abdominal pain—Methotrexate—esophageal cancer	5.81e-05	0.000623	CcSEcCtD
Nilotinib—Body temperature increased—Methotrexate—esophageal cancer	5.81e-05	0.000623	CcSEcCtD
Nilotinib—Hypersensitivity—Methotrexate—esophageal cancer	5.42e-05	0.00058	CcSEcCtD
Nilotinib—ABCB1—lymph node—esophageal cancer	5.32e-05	0.000632	CbGeAlD
Nilotinib—Asthenia—Methotrexate—esophageal cancer	5.27e-05	0.000565	CcSEcCtD
Nilotinib—Pruritus—Methotrexate—esophageal cancer	5.2e-05	0.000557	CcSEcCtD
Nilotinib—Diarrhoea—Methotrexate—esophageal cancer	5.03e-05	0.000539	CcSEcCtD
Nilotinib—Dizziness—Methotrexate—esophageal cancer	4.86e-05	0.000521	CcSEcCtD
Nilotinib—Vomiting—Methotrexate—esophageal cancer	4.67e-05	0.000501	CcSEcCtD
Nilotinib—Rash—Methotrexate—esophageal cancer	4.63e-05	0.000497	CcSEcCtD
Nilotinib—Dermatitis—Methotrexate—esophageal cancer	4.63e-05	0.000496	CcSEcCtD
Nilotinib—Headache—Methotrexate—esophageal cancer	4.61e-05	0.000493	CcSEcCtD
Nilotinib—Nausea—Methotrexate—esophageal cancer	4.37e-05	0.000468	CcSEcCtD
Nilotinib—MAP2K5—Signaling Pathways—CDKN1A—esophageal cancer	2.07e-06	1.21e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CREBBP—esophageal cancer	2.07e-06	1.21e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CDKN1A—esophageal cancer	2.06e-06	1.21e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NOTCH1—esophageal cancer	2.06e-06	1.2e-05	CbGpPWpGaD
Nilotinib—CA2—Metabolism—PIK3CA—esophageal cancer	2.05e-06	1.2e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—CREBBP—esophageal cancer	2.04e-06	1.2e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—MYC—esophageal cancer	2.04e-06	1.19e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—ERBB2—esophageal cancer	2.03e-06	1.19e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KDR—esophageal cancer	2.03e-06	1.19e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CDKN1A—esophageal cancer	2.02e-06	1.18e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTT1—esophageal cancer	2.01e-06	1.18e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NOTCH1—esophageal cancer	2.01e-06	1.18e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—EP300—esophageal cancer	2.01e-06	1.18e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—ERBB2—esophageal cancer	2.01e-06	1.18e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CDKN1A—esophageal cancer	2.01e-06	1.18e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS1—esophageal cancer	2e-06	1.17e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ENO1—esophageal cancer	2e-06	1.17e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—PIK3CA—esophageal cancer	2e-06	1.17e-05	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2e-06	1.17e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTT1—esophageal cancer	2e-06	1.17e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—BCL2—esophageal cancer	2e-06	1.17e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—EGFR—esophageal cancer	1.99e-06	1.17e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CYP2A6—esophageal cancer	1.99e-06	1.17e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—HMOX1—esophageal cancer	1.98e-06	1.16e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.98e-06	1.16e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYP2A6—esophageal cancer	1.97e-06	1.16e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PSME2—esophageal cancer	1.97e-06	1.16e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PSME1—esophageal cancer	1.97e-06	1.16e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—EP300—esophageal cancer	1.97e-06	1.15e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.97e-06	1.15e-05	CbGpPWpGaD
Nilotinib—CA1—Metabolism—PIK3CA—esophageal cancer	1.97e-06	1.15e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ADH1B—esophageal cancer	1.97e-06	1.15e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—EP300—esophageal cancer	1.96e-06	1.15e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—EGFR—esophageal cancer	1.96e-06	1.15e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NOS3—esophageal cancer	1.96e-06	1.15e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CYP1B1—esophageal cancer	1.96e-06	1.14e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—ERBB2—esophageal cancer	1.94e-06	1.13e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—EP300—esophageal cancer	1.92e-06	1.13e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—PIK3CA—esophageal cancer	1.92e-06	1.13e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CDKN1A—esophageal cancer	1.92e-06	1.12e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—EP300—esophageal cancer	1.91e-06	1.12e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—NOS3—esophageal cancer	1.91e-06	1.12e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NOTCH1—esophageal cancer	1.91e-06	1.12e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CDKN1A—esophageal cancer	1.91e-06	1.12e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ABCB1—esophageal cancer	1.9e-06	1.11e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—PIK3CA—esophageal cancer	1.89e-06	1.11e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ENO1—esophageal cancer	1.89e-06	1.1e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS1—esophageal cancer	1.89e-06	1.1e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TYMP—esophageal cancer	1.88e-06	1.1e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS1—esophageal cancer	1.87e-06	1.1e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ENO1—esophageal cancer	1.87e-06	1.1e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CREBBP—esophageal cancer	1.87e-06	1.09e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PSME1—esophageal cancer	1.86e-06	1.09e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PSME2—esophageal cancer	1.86e-06	1.09e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—EGFR—esophageal cancer	1.86e-06	1.09e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NOS3—esophageal cancer	1.85e-06	1.08e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—MYC—esophageal cancer	1.85e-06	1.08e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PSME1—esophageal cancer	1.84e-06	1.08e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PSME2—esophageal cancer	1.84e-06	1.08e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CYP19A1—esophageal cancer	1.84e-06	1.08e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HIF1A—esophageal cancer	1.83e-06	1.07e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—ERBB2—esophageal cancer	1.83e-06	1.07e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—NOS3—esophageal cancer	1.83e-06	1.07e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP26A1—esophageal cancer	1.83e-06	1.07e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CREBBP—esophageal cancer	1.83e-06	1.07e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—EP300—esophageal cancer	1.82e-06	1.07e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—EP300—esophageal cancer	1.81e-06	1.06e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—EGFR—esophageal cancer	1.81e-06	1.06e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MYC—esophageal cancer	1.81e-06	1.06e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CCND1—esophageal cancer	1.79e-06	1.05e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—ERBB2—esophageal cancer	1.79e-06	1.05e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALOX15—esophageal cancer	1.78e-06	1.04e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CCND1—esophageal cancer	1.78e-06	1.04e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—EGFR—esophageal cancer	1.77e-06	1.03e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—MYC—esophageal cancer	1.75e-06	1.03e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KDR—esophageal cancer	1.75e-06	1.03e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—PTGS2—esophageal cancer	1.75e-06	1.02e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CDKN1A—esophageal cancer	1.74e-06	1.02e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—CREBBP—esophageal cancer	1.73e-06	1.01e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—ERBB2—esophageal cancer	1.73e-06	1.01e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CREBBP—esophageal cancer	1.73e-06	1.01e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—PIK3CA—esophageal cancer	1.73e-06	1.01e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—PIK3CA—esophageal cancer	1.73e-06	1.01e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CDKN1A—esophageal cancer	1.72e-06	1.01e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MYC—esophageal cancer	1.72e-06	1.01e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—EGFR—esophageal cancer	1.72e-06	1e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—PIK3CA—esophageal cancer	1.7e-06	9.97e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CYP1B1—esophageal cancer	1.7e-06	9.97e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TPI1—esophageal cancer	1.7e-06	9.94e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTO1—esophageal cancer	1.7e-06	9.94e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—EGFR—esophageal cancer	1.68e-06	9.83e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—HMOX1—esophageal cancer	1.68e-06	9.82e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—EGFR—esophageal cancer	1.67e-06	9.8e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTGS2—esophageal cancer	1.67e-06	9.79e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NOS3—esophageal cancer	1.67e-06	9.77e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—CDKN1A—esophageal cancer	1.66e-06	9.7e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EP300—esophageal cancer	1.65e-06	9.67e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NOTCH1—esophageal cancer	1.65e-06	9.66e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.65e-06	9.63e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—EGFR—esophageal cancer	1.64e-06	9.59e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EP300—esophageal cancer	1.64e-06	9.58e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NOS3—esophageal cancer	1.63e-06	9.57e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—EGFR—esophageal cancer	1.63e-06	9.55e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALDOB—esophageal cancer	1.63e-06	9.53e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CCND1—esophageal cancer	1.62e-06	9.47e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—PIK3CA—esophageal cancer	1.61e-06	9.44e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.61e-06	9.42e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ABCB1—esophageal cancer	1.61e-06	9.42e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CYP1B1—esophageal cancer	1.61e-06	9.39e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CYP19A1—esophageal cancer	1.6e-06	9.37e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYP1B1—esophageal cancer	1.59e-06	9.31e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—MYC—esophageal cancer	1.58e-06	9.25e-06	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—MYC—esophageal cancer	1.58e-06	9.25e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—EP300—esophageal cancer	1.58e-06	9.23e-06	CbGpPWpGaD
Nilotinib—KIT—Disease—PIK3CA—esophageal cancer	1.57e-06	9.21e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GAPDH—esophageal cancer	1.57e-06	9.17e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CDKN1A—esophageal cancer	1.57e-06	9.16e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—ERBB2—esophageal cancer	1.56e-06	9.14e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—EGFR—esophageal cancer	1.55e-06	9.09e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CRABP1—esophageal cancer	1.55e-06	9.09e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—NOS3—esophageal cancer	1.55e-06	9.08e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NOS3—esophageal cancer	1.55e-06	9.07e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—EGFR—esophageal cancer	1.55e-06	9.05e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—PIK3CA—esophageal cancer	1.53e-06	8.97e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CCND1—esophageal cancer	1.53e-06	8.96e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—CDKN1A—esophageal cancer	1.53e-06	8.95e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—ERBB2—esophageal cancer	1.53e-06	8.95e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CYP19A1—esophageal cancer	1.51e-06	8.83e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CREBBP—esophageal cancer	1.5e-06	8.76e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYP19A1—esophageal cancer	1.5e-06	8.75e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EP300—esophageal cancer	1.49e-06	8.72e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—PIK3CA—esophageal cancer	1.49e-06	8.72e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—esophageal cancer	1.48e-06	8.68e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CDKN1A—esophageal cancer	1.48e-06	8.67e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GNG7—esophageal cancer	1.48e-06	8.65e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—HMOX1—esophageal cancer	1.46e-06	8.55e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—PIK3CA—esophageal cancer	1.46e-06	8.53e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—EP300—esophageal cancer	1.46e-06	8.52e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—PIK3CA—esophageal cancer	1.45e-06	8.5e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ERBB2—esophageal cancer	1.45e-06	8.48e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MYC—esophageal cancer	1.44e-06	8.42e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MYC—esophageal cancer	1.43e-06	8.34e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—PIK3CA—esophageal cancer	1.42e-06	8.33e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTGS2—esophageal cancer	1.42e-06	8.31e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—PIK3CA—esophageal cancer	1.42e-06	8.29e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—esophageal cancer	1.41e-06	8.25e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EP300—esophageal cancer	1.41e-06	8.25e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EGFR—esophageal cancer	1.41e-06	8.24e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EGFR—esophageal cancer	1.39e-06	8.16e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—EP300—esophageal cancer	1.39e-06	8.14e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.38e-06	8.1e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCND1—esophageal cancer	1.38e-06	8.07e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—HMOX1—esophageal cancer	1.38e-06	8.06e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—HMOX1—esophageal cancer	1.37e-06	7.99e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCND1—esophageal cancer	1.35e-06	7.91e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—PIK3CA—esophageal cancer	1.35e-06	7.89e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—EGFR—esophageal cancer	1.34e-06	7.86e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PIK3CA—esophageal cancer	1.34e-06	7.85e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NOS3—esophageal cancer	1.34e-06	7.84e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.34e-06	7.84e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CDKN1A—esophageal cancer	1.33e-06	7.81e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ABCB1—esophageal cancer	1.32e-06	7.73e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.32e-06	7.71e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ABCB1—esophageal cancer	1.31e-06	7.67e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CDKN1A—esophageal cancer	1.31e-06	7.65e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.3e-06	7.62e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MYC—esophageal cancer	1.3e-06	7.59e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCND1—esophageal cancer	1.28e-06	7.49e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CREBBP—esophageal cancer	1.27e-06	7.44e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EP300—esophageal cancer	1.27e-06	7.43e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EGFR—esophageal cancer	1.27e-06	7.43e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—MYC—esophageal cancer	1.27e-06	7.42e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ERBB2—esophageal cancer	1.25e-06	7.33e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EP300—esophageal cancer	1.24e-06	7.28e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—EGFR—esophageal cancer	1.24e-06	7.26e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CDKN1A—esophageal cancer	1.24e-06	7.25e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.23e-06	7.22e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ENO1—esophageal cancer	1.23e-06	7.22e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MYC—esophageal cancer	1.23e-06	7.19e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PIK3CA—esophageal cancer	1.22e-06	7.15e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.22e-06	7.12e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PSME2—esophageal cancer	1.22e-06	7.12e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PSME1—esophageal cancer	1.22e-06	7.12e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PIK3CA—esophageal cancer	1.21e-06	7.08e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EGFR—esophageal cancer	1.2e-06	7.03e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—esophageal cancer	1.18e-06	6.92e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—EP300—esophageal cancer	1.18e-06	6.91e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EP300—esophageal cancer	1.18e-06	6.9e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—esophageal cancer	1.17e-06	6.85e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—PIK3CA—esophageal cancer	1.17e-06	6.82e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—NOS3—esophageal cancer	1.14e-06	6.66e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCND1—esophageal cancer	1.11e-06	6.48e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MYC—esophageal cancer	1.11e-06	6.48e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PIK3CA—esophageal cancer	1.1e-06	6.45e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MYC—esophageal cancer	1.08e-06	6.34e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EGFR—esophageal cancer	1.08e-06	6.34e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—PIK3CA—esophageal cancer	1.08e-06	6.3e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CREBBP—esophageal cancer	1.08e-06	6.3e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CDKN1A—esophageal cancer	1.07e-06	6.27e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—esophageal cancer	1.07e-06	6.24e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EGFR—esophageal cancer	1.06e-06	6.2e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.05e-06	6.14e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PIK3CA—esophageal cancer	1.04e-06	6.1e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—esophageal cancer	1.04e-06	6.09e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PIK3CA—esophageal cancer	1.03e-06	6.02e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MYC—esophageal cancer	1.03e-06	6.01e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EP300—esophageal cancer	1.02e-06	5.96e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—esophageal cancer	1.01e-06	5.9e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EGFR—esophageal cancer	1e-06	5.88e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	9.91e-07	5.8e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP19A1—esophageal cancer	9.87e-07	5.77e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—NOS3—esophageal cancer	9.63e-07	5.64e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PIK3CA—esophageal cancer	9.4e-07	5.5e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CREBBP—esophageal cancer	9.37e-07	5.49e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PIK3CA—esophageal cancer	9.2e-07	5.38e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—esophageal cancer	9.09e-07	5.32e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HMOX1—esophageal cancer	9e-07	5.27e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—esophageal cancer	8.9e-07	5.21e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MYC—esophageal cancer	8.88e-07	5.2e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CREBBP—esophageal cancer	8.83e-07	5.17e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—esophageal cancer	8.81e-07	5.16e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CREBBP—esophageal cancer	8.76e-07	5.12e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PIK3CA—esophageal cancer	8.74e-07	5.11e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PIK3CA—esophageal cancer	8.72e-07	5.1e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EGFR—esophageal cancer	8.69e-07	5.08e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—EP300—esophageal cancer	8.66e-07	5.07e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ABCB1—esophageal cancer	8.64e-07	5.06e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—esophageal cancer	8.44e-07	4.94e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—NOS3—esophageal cancer	8.39e-07	4.91e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—NOS3—esophageal cancer	7.91e-07	4.63e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—NOS3—esophageal cancer	7.84e-07	4.59e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—esophageal cancer	7.68e-07	4.49e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CA—esophageal cancer	7.54e-07	4.41e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—EP300—esophageal cancer	7.33e-07	4.29e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—esophageal cancer	7.29e-07	4.27e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—esophageal cancer	7.23e-07	4.23e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—esophageal cancer	7.17e-07	4.2e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CA—esophageal cancer	6.4e-07	3.75e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—EP300—esophageal cancer	6.38e-07	3.74e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—EP300—esophageal cancer	6.02e-07	3.52e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—EP300—esophageal cancer	5.96e-07	3.49e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CREBBP—esophageal cancer	5.78e-07	3.38e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CA—esophageal cancer	5.42e-07	3.17e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NOS3—esophageal cancer	5.17e-07	3.03e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—esophageal cancer	4.73e-07	2.77e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CA—esophageal cancer	4.72e-07	2.76e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CA—esophageal cancer	4.45e-07	2.6e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CA—esophageal cancer	4.41e-07	2.58e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—EP300—esophageal cancer	3.93e-07	2.3e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CA—esophageal cancer	2.91e-07	1.7e-06	CbGpPWpGaD
